Share Price and Basic Stock Data
Last Updated: October 28, 2025, 7:27 pm
| PEG Ratio | 2.88 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Torrent Pharmaceuticals Ltd, operating in the pharmaceuticals sector, reported a market capitalization of ₹1,20,897 Cr and a share price of ₹3,572. The company has demonstrated consistent revenue growth, with sales rising from ₹8,508 Cr in March 2022 to ₹9,620 Cr in March 2023, and further increasing to ₹10,728 Cr in March 2024. The trailing twelve months (TTM) revenue stood at ₹11,835 Cr, indicating a robust upward trajectory. Quarterly sales figures reflect this trend, with revenues rising from ₹2,347 Cr in June 2022 to ₹2,660 Cr in September 2023. The company’s operating profit margin (OPM) has also shown resilience, standing at 32% for the latest quarter, with a reported operating profit of ₹3,368 Cr for the financial year ending March 2024. This growth can be attributed to strong product demand and effective cost management strategies, positioning Torrent favorably within the competitive landscape of the pharmaceutical industry.
Profitability and Efficiency Metrics
Torrent Pharmaceuticals reported a net profit of ₹2,002 Cr, translating to a remarkable return on equity (ROE) of 26.5% and return on capital employed (ROCE) of 27.0%. These figures are indicative of the company’s efficient use of capital and strong profitability relative to its equity base. The gross profit margins remained healthy at 32%, with operating profit increasing consistently, reflecting the company’s ability to manage expenses effectively. The interest coverage ratio (ICR) stood at 14.84x, signaling robust capacity to meet interest obligations. However, the cash conversion cycle (CCC) was recorded at 154 days, suggesting potential inefficiencies in working capital management. The earnings per share (EPS) increased from ₹36.79 in March 2023 to ₹56.47 in March 2025, illustrating significant growth in profitability per share, which enhances shareholder value and confidence.
Balance Sheet Strength and Financial Ratios
The financial position of Torrent Pharmaceuticals is underpinned by a solid balance sheet, with total assets amounting to ₹14,396 Cr as of March 2025. The company maintained reserves of ₹7,421 Cr, reflecting a strong equity base. Total borrowings were reported at ₹3,202 Cr, resulting in a low long-term debt-to-equity ratio of 0.15, which suggests prudent leverage and minimal financial risk. The current ratio stood at 1.19, indicating adequate liquidity to cover short-term obligations. Additionally, the price-to-book value (P/BV) ratio was recorded at 14.42x, significantly higher than the industry average, suggesting that the stock is valued at a premium, reflecting investor confidence in the company’s growth prospects. However, the high P/BV could also indicate overvaluation risks if growth expectations are not met.
Shareholding Pattern and Investor Confidence
The shareholding structure of Torrent Pharmaceuticals reveals a strong promoter holding at 68.31%, with foreign institutional investors (FIIs) at 15.92% and domestic institutional investors (DIIs) at 9.17%. The consistent promoter stake indicates a commitment to the company’s long-term strategy. The number of shareholders increased to 78,226, reflecting growing investor interest and confidence. However, FII ownership showed slight fluctuations, peaking at 16.31% in March 2025, which may suggest a cautious sentiment among foreign investors. The decline in public shareholding to 6.47% could indicate a concentration of ownership, which may raise concerns regarding liquidity. The company’s ability to maintain investor confidence will depend on its continued financial performance and strategic initiatives.
Outlook, Risks, and Final Insight
Looking forward, Torrent Pharmaceuticals is positioned for sustained growth, driven by its strong revenue trajectory and profitability metrics. However, risks include potential regulatory hurdles and increased competition in the pharmaceutical sector, which could impact margins. The high cash conversion cycle could also pose challenges in working capital management. While the company’s financial health is robust, it must navigate these risks effectively to maintain its growth momentum. The outlook remains positive, contingent on the company’s ability to innovate and adapt to changing market dynamics. Should Torrent continue on its current path, it may solidify its position as a leading player in the pharmaceutical industry, while any setbacks could necessitate strategic re-evaluations to safeguard its market position and investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Torrent Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 144 Cr. | 114 | 247/84.3 | 32.8 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.80 Cr. | 1.99 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,983 Cr. | 460 | 479/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.6 Cr. | 48.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.2 Cr. | 22.0 | 29.1/17.0 | 33.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,766.58 Cr | 1,179.77 | 50.40 | 194.36 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,347 | 2,291 | 2,491 | 2,491 | 2,591 | 2,660 | 2,732 | 2,745 | 2,859 | 2,889 | 2,809 | 2,959 | 3,178 |
| Expenses | 1,635 | 1,612 | 1,767 | 1,764 | 1,800 | 1,835 | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 | 1,995 | 2,146 |
| Operating Profit | 712 | 679 | 724 | 727 | 791 | 825 | 869 | 883 | 904 | 939 | 914 | 964 | 1,032 |
| OPM % | 30% | 30% | 29% | 29% | 31% | 31% | 32% | 32% | 32% | 32% | 33% | 33% | 32% |
| Other Income | 30 | 16 | -10 | 9 | 34 | 26 | 55 | 31 | 24 | -16 | 33 | -42 | -37 |
| Interest | 55 | 69 | 102 | 107 | 103 | 91 | 80 | 80 | 75 | 64 | 57 | 56 | 56 |
| Depreciation | 155 | 163 | 193 | 196 | 191 | 201 | 213 | 203 | 197 | 198 | 199 | 201 | 201 |
| Profit before tax | 532 | 463 | 419 | 433 | 531 | 559 | 631 | 631 | 656 | 661 | 691 | 665 | 738 |
| Tax % | 33% | 33% | 30% | 34% | 29% | 31% | 30% | 29% | 30% | 31% | 27% | 25% | 26% |
| Net Profit | 354 | 312 | 292 | 287 | 378 | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 |
| EPS in Rs | 10.46 | 9.22 | 8.63 | 8.48 | 11.17 | 11.41 | 13.09 | 13.27 | 13.50 | 13.39 | 14.86 | 14.71 | 16.19 |
Last Updated: August 1, 2025, 10:10 am
Below is a detailed analysis of the quarterly data for Torrent Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 3,178.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,959.00 Cr. (Mar 2025) to 3,178.00 Cr., marking an increase of 219.00 Cr..
- For Expenses, as of Jun 2025, the value is 2,146.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,995.00 Cr. (Mar 2025) to 2,146.00 Cr., marking an increase of 151.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 1,032.00 Cr.. The value appears strong and on an upward trend. It has increased from 964.00 Cr. (Mar 2025) to 1,032.00 Cr., marking an increase of 68.00 Cr..
- For OPM %, as of Jun 2025, the value is 32.00%. The value appears to be declining and may need further review. It has decreased from 33.00% (Mar 2025) to 32.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is -37.00 Cr.. The value appears strong and on an upward trend. It has increased from -42.00 Cr. (Mar 2025) to -37.00 Cr., marking an increase of 5.00 Cr..
- For Interest, as of Jun 2025, the value is 56.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 56.00 Cr..
- For Depreciation, as of Jun 2025, the value is 201.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 201.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 738.00 Cr.. The value appears strong and on an upward trend. It has increased from 665.00 Cr. (Mar 2025) to 738.00 Cr., marking an increase of 73.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Mar 2025) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 548.00 Cr.. The value appears strong and on an upward trend. It has increased from 498.00 Cr. (Mar 2025) to 548.00 Cr., marking an increase of 50.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 16.19. The value appears strong and on an upward trend. It has increased from 14.71 (Mar 2025) to 16.19, marking an increase of 1.48.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,172 | 4,636 | 6,687 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,516 | 11,835 |
| Expenses | 3,216 | 3,616 | 3,954 | 4,438 | 4,601 | 5,690 | 5,769 | 5,524 | 6,077 | 6,778 | 7,360 | 7,795 | 7,986 |
| Operating Profit | 955 | 1,020 | 2,733 | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,721 | 3,849 |
| OPM % | 23% | 22% | 41% | 24% | 23% | 26% | 27% | 31% | 29% | 30% | 31% | 32% | 33% |
| Other Income | 34 | 286 | 32 | 223 | 299 | -300 | 121 | 57 | -288 | 45 | 146 | -1 | -62 |
| Interest | 59 | 175 | 184 | 206 | 308 | 504 | 451 | 353 | 255 | 333 | 354 | 252 | 233 |
| Depreciation | 87 | 191 | 238 | 307 | 409 | 618 | 654 | 658 | 662 | 707 | 808 | 795 | 799 |
| Profit before tax | 844 | 940 | 2,343 | 1,088 | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,673 | 2,755 |
| Tax % | 21% | 20% | 26% | 14% | 27% | 22% | 14% | 18% | 37% | 33% | 30% | 28% | |
| Net Profit | 664 | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,002 |
| EPS in Rs | 19.62 | 22.19 | 51.22 | 27.59 | 20.04 | 12.89 | 30.28 | 36.99 | 22.97 | 36.79 | 48.94 | 56.47 | 59.15 |
| Dividend Payout % | 25% | 25% | 34% | 25% | 35% | 66% | 53% | 47% | 105% | 60% | 57% | 57% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 13.10% | 130.76% | -46.11% | -27.41% | -35.69% | 135.09% | 22.15% | -37.94% | 60.23% | 33.01% | 15.40% |
| Change in YoY Net Profit Growth (%) | 0.00% | 117.66% | -176.86% | 18.70% | -8.28% | 170.78% | -112.95% | -60.09% | 98.17% | -27.22% | -17.61% |
Torrent Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 8% |
| 3 Years: | 11% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 14% |
| 3 Years: | 21% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 21% |
| 3 Years: | 34% |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 23% |
| 3 Years: | 24% |
| Last Year: | 27% |
Last Updated: September 5, 2025, 1:46 pm
Balance Sheet
Last Updated: July 25, 2025, 2:11 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 |
| Reserves | 1,818 | 2,406 | 3,409 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,421 |
| Borrowings | 1,132 | 2,740 | 2,352 | 2,510 | 6,462 | 6,038 | 5,784 | 4,874 | 4,070 | 5,369 | 4,022 | 3,202 |
| Other Liabilities | 1,988 | 2,589 | 3,040 | 2,740 | 3,159 | 3,351 | 3,402 | 3,363 | 2,884 | 3,043 | 3,627 | 3,603 |
| Total Liabilities | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 |
| Fixed Assets | 875 | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,121 | 8,138 | 7,947 |
| CWIP | 534 | 678 | 1,042 | 519 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 478 |
| Investments | 186 | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 156 |
| Other Assets | 3,427 | 4,011 | 4,206 | 4,589 | 5,249 | 5,395 | 5,763 | 5,940 | 5,628 | 5,524 | 5,834 | 5,815 |
| Total Assets | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 |
Below is a detailed analysis of the balance sheet data for Torrent Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 169.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 169.00 Cr..
- For Reserves, as of Mar 2025, the value is 7,421.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,687.00 Cr. (Mar 2024) to 7,421.00 Cr., marking an increase of 734.00 Cr..
- For Borrowings, as of Mar 2025, the value is 3,202.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 4,022.00 Cr. (Mar 2024) to 3,202.00 Cr., marking a decrease of 820.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 3,603.00 Cr.. The value appears to be improving (decreasing). It has decreased from 3,627.00 Cr. (Mar 2024) to 3,603.00 Cr., marking a decrease of 24.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 14,396.00 Cr.. The value appears to be improving (decreasing). It has decreased from 14,505.00 Cr. (Mar 2024) to 14,396.00 Cr., marking a decrease of 109.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 7,947.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8,138.00 Cr. (Mar 2024) to 7,947.00 Cr., marking a decrease of 191.00 Cr..
- For CWIP, as of Mar 2025, the value is 478.00 Cr.. The value appears strong and on an upward trend. It has increased from 361.00 Cr. (Mar 2024) to 478.00 Cr., marking an increase of 117.00 Cr..
- For Investments, as of Mar 2025, the value is 156.00 Cr.. The value appears to be declining and may need further review. It has decreased from 173.00 Cr. (Mar 2024) to 156.00 Cr., marking a decrease of 17.00 Cr..
- For Other Assets, as of Mar 2025, the value is 5,815.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,834.00 Cr. (Mar 2024) to 5,815.00 Cr., marking a decrease of 19.00 Cr..
- For Total Assets, as of Mar 2025, the value is 14,396.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14,505.00 Cr. (Mar 2024) to 14,396.00 Cr., marking a decrease of 109.00 Cr..
Notably, the Reserves (7,421.00 Cr.) exceed the Borrowings (3,202.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 954.00 | -1.00 | 0.00 | -1.00 | -5.00 | -5.00 | -3.00 | -2.00 | -2.00 | -3.00 | -1.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 96 | 125 | 79 | 60 | 77 | 68 | 76 | 69 | 70 | 74 | 63 | 59 |
| Inventory Days | 297 | 275 | 314 | 318 | 429 | 318 | 362 | 456 | 368 | 298 | 310 | 334 |
| Days Payable | 421 | 472 | 523 | 356 | 447 | 345 | 345 | 351 | 250 | 224 | 284 | 239 |
| Cash Conversion Cycle | -28 | -71 | -130 | 21 | 59 | 42 | 93 | 174 | 188 | 147 | 89 | 154 |
| Working Capital Days | 24 | 29 | -1 | 28 | -80 | -62 | -52 | -5 | 7 | -33 | -27 | 7 |
| ROCE % | 35% | 27% | 48% | 19% | 13% | 13% | 15% | 17% | 19% | 20% | 23% | 27% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Kotak Emerging Equity Fund - Regular Plan | 2,309,253 | 1.5 | 584.5 | 2,309,253 | 2025-04-22 17:25:17 | 0% |
| UTI Flexi Cap Fund | 1,233,512 | 1.24 | 312.21 | 1,233,512 | 2025-04-22 17:25:17 | 0% |
| SBI Large & Midcap Fund | 740,002 | 0.94 | 187.3 | 740,002 | 2025-04-22 17:25:17 | 0% |
| Nippon India Pharma Fund | 603,364 | 2.22 | 152.72 | 603,364 | 2025-04-22 17:25:17 | 0% |
| Kotak Small Cap Fund - Regular Plan | 463,748 | 0.81 | 117.38 | 463,748 | 2025-04-22 17:25:17 | 0% |
| Axis Growth Opportunities Fund | 400,340 | 0.93 | 101.33 | 400,340 | 2025-04-22 17:25:17 | 0% |
| Kotak Equity Arbitrage Fund - Regular Plan | 390,500 | 0.27 | 98.84 | 390,500 | 2025-04-22 17:25:17 | 0% |
| Nippon India Value Fund | 353,626 | 1.28 | 89.51 | 353,626 | 2025-04-22 17:25:17 | 0% |
| Franklin India Bluechip Fund - Dividend | 350,000 | 1.19 | 88.59 | 350,000 | 2025-04-22 17:25:17 | 0% |
| Franklin India Bluechip Fund - Growth | 350,000 | 1.19 | 88.59 | 350,000 | 2025-04-22 17:25:17 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 56.47 | 48.94 | 36.79 | 45.93 | 73.98 |
| Diluted EPS (Rs.) | 56.47 | 48.94 | 36.79 | 45.93 | 73.98 |
| Cash EPS (Rs.) | 79.96 | 72.82 | 57.67 | 85.05 | 112.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 224.27 | 202.57 | 183.13 | 351.75 | 344.90 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 224.27 | 202.57 | 183.13 | 351.75 | 344.90 |
| Revenue From Operations / Share (Rs.) | 340.25 | 316.96 | 284.23 | 502.72 | 472.97 |
| PBDIT / Share (Rs.) | 110.63 | 101.21 | 85.30 | 155.27 | 149.90 |
| PBIT / Share (Rs.) | 87.14 | 77.33 | 64.43 | 116.15 | 111.04 |
| PBT / Share (Rs.) | 78.97 | 69.49 | 54.58 | 72.44 | 90.18 |
| Net Profit / Share (Rs.) | 56.47 | 48.94 | 36.79 | 45.92 | 73.97 |
| NP After MI And SOA / Share (Rs.) | 56.47 | 48.94 | 36.79 | 45.92 | 73.97 |
| PBDIT Margin (%) | 32.51 | 31.93 | 30.01 | 30.88 | 31.69 |
| PBIT Margin (%) | 25.61 | 24.39 | 22.66 | 23.10 | 23.47 |
| PBT Margin (%) | 23.20 | 21.92 | 19.20 | 14.40 | 19.06 |
| Net Profit Margin (%) | 16.59 | 15.44 | 12.94 | 9.13 | 15.63 |
| NP After MI And SOA Margin (%) | 16.59 | 15.44 | 12.94 | 9.13 | 15.63 |
| Return on Networth / Equity (%) | 25.17 | 24.15 | 20.09 | 13.05 | 21.44 |
| Return on Capital Employeed (%) | 28.71 | 27.16 | 22.79 | 22.63 | 20.46 |
| Return On Assets (%) | 12.75 | 10.99 | 8.29 | 5.93 | 8.89 |
| Long Term Debt / Equity (X) | 0.15 | 0.23 | 0.40 | 0.35 | 0.50 |
| Total Debt / Equity (X) | 0.39 | 0.57 | 0.85 | 0.67 | 0.82 |
| Asset Turnover Ratio (%) | 0.76 | 0.71 | 0.68 | 0.53 | 0.50 |
| Current Ratio (X) | 1.19 | 1.03 | 0.97 | 1.20 | 1.13 |
| Quick Ratio (X) | 0.65 | 0.61 | 0.56 | 0.64 | 0.58 |
| Inventory Turnover Ratio (X) | 4.70 | 0.73 | 0.63 | 0.68 | 0.69 |
| Dividend Payout Ratio (NP) (%) | 56.66 | 61.29 | 69.30 | 87.09 | 27.03 |
| Dividend Payout Ratio (CP) (%) | 40.02 | 41.19 | 44.21 | 47.02 | 17.72 |
| Earning Retention Ratio (%) | 43.34 | 38.71 | 30.70 | 12.91 | 72.97 |
| Cash Earning Retention Ratio (%) | 59.98 | 58.81 | 55.79 | 52.98 | 82.28 |
| Interest Coverage Ratio (X) | 14.84 | 9.69 | 8.66 | 10.30 | 7.19 |
| Interest Coverage Ratio (Post Tax) (X) | 8.67 | 5.43 | 4.73 | 5.95 | 4.55 |
| Enterprise Value (Cr.) | 111924.90 | 91136.90 | 56758.99 | 50939.27 | 47229.23 |
| EV / Net Operating Revenue (X) | 9.72 | 8.50 | 5.90 | 5.99 | 5.90 |
| EV / EBITDA (X) | 29.89 | 26.60 | 19.66 | 19.38 | 18.62 |
| MarketCap / Net Operating Revenue (X) | 9.51 | 8.21 | 5.41 | 5.56 | 5.37 |
| Retention Ratios (%) | 43.33 | 38.70 | 30.69 | 12.90 | 72.96 |
| Price / BV (X) | 14.42 | 12.84 | 8.39 | 7.95 | 7.37 |
| Price / Net Operating Revenue (X) | 9.51 | 8.21 | 5.41 | 5.56 | 5.37 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.01 | 0.02 |
After reviewing the key financial ratios for Torrent Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
- For Diluted EPS (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
- For Cash EPS (Rs.), as of Mar 25, the value is 79.96. This value is within the healthy range. It has increased from 72.82 (Mar 24) to 79.96, marking an increase of 7.14.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 224.27. It has increased from 202.57 (Mar 24) to 224.27, marking an increase of 21.70.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 224.27. It has increased from 202.57 (Mar 24) to 224.27, marking an increase of 21.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 340.25. It has increased from 316.96 (Mar 24) to 340.25, marking an increase of 23.29.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 110.63. This value is within the healthy range. It has increased from 101.21 (Mar 24) to 110.63, marking an increase of 9.42.
- For PBIT / Share (Rs.), as of Mar 25, the value is 87.14. This value is within the healthy range. It has increased from 77.33 (Mar 24) to 87.14, marking an increase of 9.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 78.97. This value is within the healthy range. It has increased from 69.49 (Mar 24) to 78.97, marking an increase of 9.48.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
- For PBDIT Margin (%), as of Mar 25, the value is 32.51. This value is within the healthy range. It has increased from 31.93 (Mar 24) to 32.51, marking an increase of 0.58.
- For PBIT Margin (%), as of Mar 25, the value is 25.61. This value exceeds the healthy maximum of 20. It has increased from 24.39 (Mar 24) to 25.61, marking an increase of 1.22.
- For PBT Margin (%), as of Mar 25, the value is 23.20. This value is within the healthy range. It has increased from 21.92 (Mar 24) to 23.20, marking an increase of 1.28.
- For Net Profit Margin (%), as of Mar 25, the value is 16.59. This value exceeds the healthy maximum of 10. It has increased from 15.44 (Mar 24) to 16.59, marking an increase of 1.15.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.59. This value is within the healthy range. It has increased from 15.44 (Mar 24) to 16.59, marking an increase of 1.15.
- For Return on Networth / Equity (%), as of Mar 25, the value is 25.17. This value is within the healthy range. It has increased from 24.15 (Mar 24) to 25.17, marking an increase of 1.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 28.71. This value is within the healthy range. It has increased from 27.16 (Mar 24) to 28.71, marking an increase of 1.55.
- For Return On Assets (%), as of Mar 25, the value is 12.75. This value is within the healthy range. It has increased from 10.99 (Mar 24) to 12.75, marking an increase of 1.76.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.15. This value is below the healthy minimum of 0.2. It has decreased from 0.23 (Mar 24) to 0.15, marking a decrease of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.39. This value is within the healthy range. It has decreased from 0.57 (Mar 24) to 0.39, marking a decrease of 0.18.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has increased from 0.71 (Mar 24) to 0.76, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.19. This value is below the healthy minimum of 1.5. It has increased from 1.03 (Mar 24) to 1.19, marking an increase of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has increased from 0.61 (Mar 24) to 0.65, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.70. This value is within the healthy range. It has increased from 0.73 (Mar 24) to 4.70, marking an increase of 3.97.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 56.66. This value exceeds the healthy maximum of 50. It has decreased from 61.29 (Mar 24) to 56.66, marking a decrease of 4.63.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 40.02. This value is within the healthy range. It has decreased from 41.19 (Mar 24) to 40.02, marking a decrease of 1.17.
- For Earning Retention Ratio (%), as of Mar 25, the value is 43.34. This value is within the healthy range. It has increased from 38.71 (Mar 24) to 43.34, marking an increase of 4.63.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 59.98. This value is within the healthy range. It has increased from 58.81 (Mar 24) to 59.98, marking an increase of 1.17.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 14.84. This value is within the healthy range. It has increased from 9.69 (Mar 24) to 14.84, marking an increase of 5.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.67. This value is within the healthy range. It has increased from 5.43 (Mar 24) to 8.67, marking an increase of 3.24.
- For Enterprise Value (Cr.), as of Mar 25, the value is 111,924.90. It has increased from 91,136.90 (Mar 24) to 111,924.90, marking an increase of 20,788.00.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.72. This value exceeds the healthy maximum of 3. It has increased from 8.50 (Mar 24) to 9.72, marking an increase of 1.22.
- For EV / EBITDA (X), as of Mar 25, the value is 29.89. This value exceeds the healthy maximum of 15. It has increased from 26.60 (Mar 24) to 29.89, marking an increase of 3.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has increased from 8.21 (Mar 24) to 9.51, marking an increase of 1.30.
- For Retention Ratios (%), as of Mar 25, the value is 43.33. This value is within the healthy range. It has increased from 38.70 (Mar 24) to 43.33, marking an increase of 4.63.
- For Price / BV (X), as of Mar 25, the value is 14.42. This value exceeds the healthy maximum of 3. It has increased from 12.84 (Mar 24) to 14.42, marking an increase of 1.58.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has increased from 8.21 (Mar 24) to 9.51, marking an increase of 1.30.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Torrent Pharmaceuticals Ltd:
- Net Profit Margin: 16.59%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 28.71% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 25.17% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.67
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.65
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 60 (Industry average Stock P/E: 50.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.39
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.59%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Torrent House, Off Ashram Road, Ahmedabad Gujarat 380009 | investorservices@torrentpharma.com http://www.torrentpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sudhir Mehta | Chairman Emeritus |
| Mr. Samir Mehta | Executive Chairman |
| Mr. Aman Samir Mehta | Whole Time Director |
| Mr. Jinal Mehta | Non Executive Director |
| Mr. Manish Mahendra Choksi | Independent Director |
| Mr. Nikhil Khattau | Independent Director |
| Ms. Ameera Shah | Independent Director |
| Ms. Nayantara Bali | Independent Director |
FAQ
What is the intrinsic value of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd's intrinsic value (as of 28 October 2025) is 2874.64 which is 19.61% lower the current market price of 3,576.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,21,066 Cr. market cap, FY2025-2026 high/low of 3,790/2,886, reserves of ₹7,421 Cr, and liabilities of 14,396 Cr.
What is the Market Cap of Torrent Pharmaceuticals Ltd?
The Market Cap of Torrent Pharmaceuticals Ltd is 1,21,066 Cr..
What is the current Stock Price of Torrent Pharmaceuticals Ltd as on 28 October 2025?
The current stock price of Torrent Pharmaceuticals Ltd as on 28 October 2025 is 3,576.
What is the High / Low of Torrent Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Torrent Pharmaceuticals Ltd stocks is 3,790/2,886.
What is the Stock P/E of Torrent Pharmaceuticals Ltd?
The Stock P/E of Torrent Pharmaceuticals Ltd is 60.0.
What is the Book Value of Torrent Pharmaceuticals Ltd?
The Book Value of Torrent Pharmaceuticals Ltd is 224.
What is the Dividend Yield of Torrent Pharmaceuticals Ltd?
The Dividend Yield of Torrent Pharmaceuticals Ltd is 0.89 %.
What is the ROCE of Torrent Pharmaceuticals Ltd?
The ROCE of Torrent Pharmaceuticals Ltd is 27.0 %.
What is the ROE of Torrent Pharmaceuticals Ltd?
The ROE of Torrent Pharmaceuticals Ltd is 26.5 %.
What is the Face Value of Torrent Pharmaceuticals Ltd?
The Face Value of Torrent Pharmaceuticals Ltd is 5.00.